Impact of risperidone long acting injection on resource utilization in psychiatric secondary care

Journal of Psychopharmacology

Volumn 22, Issue 2, 2008, Pages 128-131

  Taylor, M ^a   Currie, A ^b   Lloyd, K ^c   Price, M ^d   Peperell, Kate ^e  

^a Springpark Centre   (United Kingdom)

^b Hadrian Clinic   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d Janssen Cilag Ltd   (United Kingdom)

^e NONE   (United Kingdom)

Author keywords

Anti psychotic agents; Health resources; Hospitalization; Length of stay; Patient compliance; Recurrence; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; LONG ACTING DRUG; RISPERIDONE;

ADULT; AGED; ARTICLE; DISEASE DURATION; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL BED; HOSPITAL BED UTILIZATION; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; RELIABILITY; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNITED KINGDOM;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; GREAT BRITAIN; HEALTH RESOURCES; HUMANS; INJECTIONS, INTRAMUSCULAR; LENGTH OF STAY; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PATIENT READMISSION; PSYCHOTIC DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; STATE MEDICINE; TREATMENT REFUSAL;

EID: 40049103778     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107084068     Document Type: Article

References (17)

1. Chue P., Eerdekens M., Augustyns I., Lachaux B., Molcan P., Eriksson L., Pretorius H., David A.S. (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111 - 117
2. Davis J.M., Chen N. (2003) Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64 (Suppl 16). 24 - 33
3. Eaddy M., Grogg A., Locklear J. (2005) Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 27: 263 - 272
4. Edwards N.C., Locklear J.C., Rupnow M F T, Diamond R.J. (2005) Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 23 (Suppl 1). 75 - 89
5. Gastpar M., Masiak M., Latif M.A., Frazzingaro S., Medori R., Lombertie E.R. (2005) Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 19 (Suppl 5). 32 - 38
6. Haycox A. (2005) Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 23 (Suppl 1). 3 - 16
7. Kane J.M. (2003) Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64 (Suppl 16). 34 - 40
8. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. (2003) Long acting injectable risperidone: efficacy and safety of the first long acting atypical antipsychotic. Am J Psych 160 (6). 1125 - 1132
9. Lang F.H., Forbes J.F., Murray G.D., Johnstone E.C. (1997) Service provision for people with schizophrenia. I. Clinical and economic perspective. Br J Psychiatry 171: 159 - 164
10. Lindenmeyer J.P., Jarboe K., Bossie C.A., Zhu Y., Mehnert A., Lasser R. (2005) Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 20: 213 - 221
11. Llorca P.M., Miadi-Fargier H., Lançon C., et al. (2005) Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 31 (2). 235 - 246
12. Love R.C. (2002) Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 59 (22 Suppl 8). S10 - 15
13. Niaz O., Haddad P.M. (2006) Three years of experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis. Psychopharmacology (abstract supplement to volume) 20 (5). A21 MB19
14. Paton C., Okocha C. (2004) Risperidone long-acting injection: the first 50 patients. Psychiatric Bull 28: 12 - 14
15. Taylor D.M., Young C.I., Mace S., Patel M.X. (2004) Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 65 (8). 1076 - 1083
16. Weiden P.J., Kozma C., Grogg A., Locklear J. (2004) Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 (8). 886 - 891
17. Young C l, Taylor D.M. (2006) Health resource utilisation associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114: 14 - 20